Vogt–Koyanagi–Harada Disease

  • Peizeng Yang
  • Zi Ye
Part of the Retina Atlas book series (RA)


Vogt–Koyanagi–Harada (VKH) disease is an autoimmune disorder characterized by bilateral granulomatous panuveitis frequently associated with multiple extraocular findings such as vitiligo, poliosis, dysacusis, alopecia, and neurological involvement. In 1906, Vogt reported a patient with nontraumatic uveitis associated with poliosis. Bilateral idiopathic uveitis patients with poliosis, vitiligo, dysacousia, and alopecia were subsequently reported by Koyanagi in 1929. Because of the uniformity of these findings, disease reported by Vogt and Koyanagi was identified as one uveitis entity and named as Vogt–Koyanagi syndrome. In 1926, a disease characterized by cerebrospinal fluid (CSF) change and retinal detachment was reported by Harada as a separate uveitis entity. Subsequently, more and more studies suggested that Vogt–Koyanagi syndrome and Harada disease are the different manifestations in different stages of the same disease. In a study on 410 Chinese VKH patients, we revealed that Harada disease is the early manifestation, whereas Vogt–Koyanagi syndrome is the feature in recurrent stage (Yang et al. 2007).


  1. Chi W, Yang P, Li B, Wu C, Jin H, Zhu X, et al. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 2007;119(5):1218–24. Scholar
  2. Cuchacovich M, Solanes F, Diaz G, Cermenati T, Avila S, Verdaguer J, et al. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2010;18(3):200–7. Scholar
  3. Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment. Prog Retin Eye Res. 2016;52:84–111. Scholar
  4. Hayasaka S, Okabe H, Takahashi J. Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol. 1982;218(1):9–13.CrossRefGoogle Scholar
  5. Hou S, Du L, Lei B, Pang CP, Zhang M, Zhuang W, et al. Genome-wide association analysis of Vogt-Koyanagi-Harada syndrome identifies two new susceptibility loci at 1p31.2 and 10q21.3. Nat Genet. 2014;46(9):1007–11. Scholar
  6. Moorthy RS, Rajeev B, Smith RE, Rao NA. Incidence and management of cataracts in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1994;118(2):197–204.CrossRefGoogle Scholar
  7. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39(4):265–92.CrossRefGoogle Scholar
  8. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an International Committee on Nomenclature. Am J Ophthalmol. 2001;131(5):647–52.CrossRefGoogle Scholar
  9. Rubsamen PE, Gass JD. Vogt-Koyanagi-Harada syndrome. Clinical course, therapy, and long-term visual outcome. Arch Ophthalmol. 1991;109(5):682–7.CrossRefGoogle Scholar
  10. Sugita S, Takase H, Kawaguchi T, Taguchi C, Mochizuki M. Cross-reaction between tyrosinase peptides and cytomegalovirus antigen by T cells from patients with Vogt-Koyanagi-Harada disease. Int Ophthalmol. 2007;27(2-3):87–95.CrossRefGoogle Scholar
  11. Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114(3):606–14. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Peizeng Yang
    • 1
  • Zi Ye
    • 1
  1. 1.The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Lab of OphthalmologyChongqing Eye InstituteChongqingPeople’s Republic of China

Personalised recommendations